Back
Gan & Lee Pharmaceuticals
Founded by : -, 1 January 1998
About the Company
Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment.
Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions.
Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.
Industry Type
According to the GICS (Global Industry Classification Standard) version of March 2023, Gan & Lee Pharmaceuticals’s industry classification falls within the following categories:
- Sector: Health Care
- Industry group: Pharmaceuticals, Biotechnology & Life Sciences
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
No preview available
Company Address
Hong Kong, Science Park, HK 新界 沙田第三期 科技大道東20E大樓1樓
Source : Google maps